A Randomized, Active-controlled, Multi-site, Double-masked, Pilot Study to Evaluate the Safety and Tolerability of QLS-111 Versus Timolol Maleate Preservative Free 0.5% Ophthalmic Solution in Subjects With Normal Tension Glaucoma (NTG)
Latest Information Update: 16 Jun 2025
At a glance
- Drugs QLS 111 (Primary)
- Indications Low tension glaucoma
- Focus Adverse reactions
- Acronyms Nightingale
- Sponsors Qlaris Bio
Most Recent Events
- 08 Jun 2025 Planned End Date changed from 22 Oct 2025 to 30 Nov 2025.
- 08 Jun 2025 Planned primary completion date changed from 15 Oct 2025 to 15 Nov 2025.
- 08 Jun 2025 Planned initiation date changed from 25 Apr 2025 to 15 Jul 2025.